parkinson's disease triple agonist glp-1 gip glucagon clinical trial

parkinson's disease triple agonist glp-1 gip glucagon clinical trial Incretin and insulin signaling as novel therapeutic targets for Alzheimer's and parkinson's disease triple agonist glp-1

Name: parkinson's disease triple agonist glp-1 gip glucagon clinical trial Incretin and insulin signaling as novel therapeutic targets for Alzheimer's and parkinson's disease triple agonist glp-1
Brand: khaima.fr
SKU: 80459250055
Price: 28.39 USD
Availability: InStock
Rating: 4.5112000000000005 (30 reviews)

SKU: 80459250055

4.5

EUR28.39 EUR59.39

Pay in 4 interest-free payments of $7.10 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Aug 19 - Aug 24

Description

Nakatani T et al

These, in turn, activate downstream transcription factors, including NF-B, EGR-1, and SP-1

Then, the cells were subjected to immunofluorescence staining for -SMA, desmin, GFAP, and vimentin (Supplementary Table 2) by an overnight incubation with primary antibodies at 4 C, followed by a 1-h incubation with secondary antibody (1:500, Molecular Probes) after a wash step